Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | RYR2 | Q92736 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261394 | 0.81 | SMN1; SMN2 (0.43) | RYR2GAALMNAMAPT | |
| SCHEMBL9353116 | 0.81 | GAA (0.42) | RYR2GAAMAPT | |
| SCHEMBL13601717 | 0.77 | MAPT (0.59) | TDP1CYP1A2KDM4ETP53HTR1A | |
| SCHEMBL303850 | 0.76 | TDP1 (0.54) | TDP1CYP1A2KDM4EATMTP53 | |
| SCHEMBL23673842 | 0.76 | ALDH1A1 (0.52) | — | |
| SCHEMBL17427968 | 0.76 | CA2 (0.45) | RYR2GAAPOLBEPHX2 | |
| SCHEMBL2956307 | 0.75 | TDP1 (0.59) | TDP1CYP1A2KDM4EHTR1APOLB | |
| SCHEMBL13607424 | 0.74 | HRH2 (0.44) | HTR1A | |
| SCHEMBL13601724 | 0.74 | MAPT (0.44) | TDP1CYP1A2KDM4EATMHTR1A | |
| SCHEMBL10121133 | 0.73 | CYP1A2 (0.64) | TDP1CYP1A2HTR1AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108408-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-4093739-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | Phenex Pharmaceuticals AG (DE) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021148628-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021148628-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2021-07-29 | — | — | WO | disclosed |
| US-20200308349-A1 | FLUROCHEMICAL PIPERAZINE CARBOXAMIDES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108408-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | AHR, ARNT, HCAR1 | TDP1 4022/4885CYP1A2 75/4885RYR2 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.